In NSCLC, several anti‐PD‐1/PD‐L1 antibodies have been studied in several treatment settings, such as first‐line, second‐line, and maintenance.6, 7, 8, 9, 10, 11. Here, CD274 is linked to non-small cell lung carcinoma.